161 related articles for article (PubMed ID: 6408176)
1. Macrophage activation: synergism between hybridoma MAF and poly(I). Poly(C) delivered by liposomes.
Pidgeon C; Schreiber RD; Schultz RM
J Immunol; 1983 Jul; 131(1):311-4. PubMed ID: 6408176
[TBL] [Abstract][Full Text] [Related]
2. Activation of tumoricidal properties in mouse macrophages by lymphokines encapsulated in liposomes.
Poste G; Kirsh R; Fogler WE; Fidler IJ
Cancer Res; 1979 Mar; 39(3):881-92. PubMed ID: 427777
[TBL] [Abstract][Full Text] [Related]
3. Activation of murine macrophages. I. Different pattern of activation by poly I:C than by lymphokine or LPS.
Taramelli D; Varesio L
J Immunol; 1981 Jul; 127(1):58-63. PubMed ID: 6787132
[TBL] [Abstract][Full Text] [Related]
4. The role of plasma membrane receptors and the kinetics of macrophage activation by lymphokines encapsulated in liposomes.
Fidler IJ; Raz A; Fogler WE; Hoyer LC; Poste G
Cancer Res; 1981 Feb; 41(2):495-504. PubMed ID: 7004633
[TBL] [Abstract][Full Text] [Related]
5. Synergism between lymphokines and muramyl dipeptide encapsulated in liposomes: in situ activation of macrophages and therapy of spontaneous cancer metastases.
Fidler IJ; Schroit AJ
J Immunol; 1984 Jul; 133(1):515-8. PubMed ID: 6373933
[TBL] [Abstract][Full Text] [Related]
6. Rat alveolar macrophages are susceptible to activation by free and liposome-encapsulated lymphokines.
Sone S; Poste G; Fidler IJ
J Immunol; 1980 May; 124(5):2197-202. PubMed ID: 7365253
[TBL] [Abstract][Full Text] [Related]
7. Preparation and antitumor effect of macrophage activating factor (MAF) encapsulated in liposomes bearing a monoclonal anti-human melanoma (A375) antibody.
Watanabe Y; Uchida E; Higuchi M; Imai Y; Osawa T
J Biol Response Mod; 1987 Oct; 6(5):556-68. PubMed ID: 3316511
[TBL] [Abstract][Full Text] [Related]
8. Macrophage activation by interferon: dissociation between tumoricidal capacity and suppressive activity.
Boraschi D; Soldateschi D; Tagliabue A
Eur J Immunol; 1982 Apr; 12(4):320-6. PubMed ID: 6178603
[TBL] [Abstract][Full Text] [Related]
9. The capacity of activated murine macrophages for augmented binding of neoplastic cells: analysis of induction by lymphokine containing MAF and kinetics of the reaction.
Marino PA; Adams DO
J Immunol; 1982 Jun; 128(6):2816-23. PubMed ID: 6804569
[TBL] [Abstract][Full Text] [Related]
10. Macrophage activation for microbicidal activity against Leishmania major: inhibition of lymphokine activation by phosphatidylcholine-phosphatidylserine liposomes.
Gilbreath MJ; Nacy CA; Hoover DL; Alving CR; Swartz GM; Meltzer MS
J Immunol; 1985 May; 134(5):3420-5. PubMed ID: 3980997
[TBL] [Abstract][Full Text] [Related]
11. Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages.
Sone S; Fidler IJ
J Immunol; 1980 Dec; 125(6):2454-60. PubMed ID: 7430635
[TBL] [Abstract][Full Text] [Related]
12. The activation of tumoricidal properties in macrophages of endotoxin responder and nonresponder mice by liposome-encapsulated immunomodulators.
Fogler WE; Talmadge JE; Fidler IJ
J Reticuloendothel Soc; 1983 Mar; 33(3):165-74. PubMed ID: 6834360
[TBL] [Abstract][Full Text] [Related]
13. Production of macrophage-activating factor by T lymphocyte clones and correlation with other lymphokine activities.
Kelso A; Glasebrook AL; Kanagawa O; Brunner KT
J Immunol; 1982 Aug; 129(2):550-6. PubMed ID: 7045227
[TBL] [Abstract][Full Text] [Related]
14. Design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages.
Fidler IJ; Raz A; Fogler WE; Kirsh R; Bugelski P; Poste G
Cancer Res; 1980 Dec; 40(12):4460-6. PubMed ID: 7002293
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of liposome-incorporation on liver macrophage activating potencies of rough lipopolysaccharide, lipid A, and muramyl dipeptide. Differences in susceptibility to lysosomal enzymes.
Daemen T; Veninga A; Dijkstra J; Scherphof G
J Immunol; 1989 Apr; 142(7):2469-74. PubMed ID: 2926140
[TBL] [Abstract][Full Text] [Related]
16. Lymphokine-mediated induction of cytolytic activity in a T cell hybridoma.
Kanagawa O; Chiller JM
J Immunol; 1985 Jan; 134(1):397-403. PubMed ID: 3917280
[TBL] [Abstract][Full Text] [Related]
17. Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators.
Fidler IJ; Barnes Z; Fogler WE; Kirsh R; Bugelski P; Poste G
Cancer Res; 1982 Feb; 42(2):496-501. PubMed ID: 7055801
[TBL] [Abstract][Full Text] [Related]
18. T-cell hybridoma production of macrophage activation factor (MAF) I. Separation of MAF from interferon gamma.
Ratliff TL; Thomasson DL; McCool RE; Catalona WJ
J Reticuloendothel Soc; 1982 May; 31(5):393-7. PubMed ID: 6181257
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of macrophage-mediated cytotoxicity: production of a soluble cytotoxic factor.
Drysdale BE; Zacharchuk CM; Shin HS
J Immunol; 1983 Nov; 131(5):2362-7. PubMed ID: 6415164
[TBL] [Abstract][Full Text] [Related]
20. [Influences of inflammatory macrophages on the proliferation of mouse tumor cells in vitro].
Sun DM; Hu XZ; Shi W; Zhang YH
Zhonghua Zhong Liu Za Zhi; 1986 Jul; 8(4):247-9. PubMed ID: 3093180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
